vg_R_D_729x729 sq.jpg

Optimise Research & Development

Read more

Strategic partners

  • Kinapse

    If your Life Sciences team are researching, developing or commercialising a new drug, Kinapse can help. Volv is pleased to work with Kinapse as they work to help Pharmaceutical clients throughout the drug development life cycle providing expert advisory, capability building and operational services.

    Read more
  • BlueCedar Networks

    We make mobile security easy to adopt, easy to manage, and available on any device. Blue Cedar is pleased to work with Volv as a strategic partner in the delivery of secure patient data to mutual customers through the Blue Cedar and Volv's mHealthSecure platforms.

    Read more
  • Bioclinica

    A speciality provider of clinical trial services. We are pleased to be working with BioClinica to integrate our solutions into the eHealth App xChange, as part of the programme for disruptive technology innovation in clinical research.

    Read More


The challenges we have set ourselves

Optimise spend in R&D

The challenge is to identify reasons for extraordinary wasted spend in R&D on dead-end research and ways to reduce it. We are bringing to market a solution to this extremely compelling problem for our customers. Using advanced predictive technologies, unassisted machine learning, artificial intelligence paradigms and web-scale technologies we are building a platform to solve the problem. We are working with customers that desire to significantly reduce their dead-end research spend. We also want to work with customers who want to invest in new research using our methodology for the early identification of medical breakthroughs.

Read more

Reducing healthcare costs

We have identified this as a priority area for volv. We are initially working on two specific areas to solve that will have a massive impact on overall healthcare spend. We are looking for progressive thinking governments and industry leaders to move our thinking forward.

Read more

Improving patient satisfaction

Our challenge is around reducing the impact on patients from adverse events and non-adherence. We have launched a product in March 2017 with a specific focus on web monitoring, social listening and literature search. We are looking for clients that want to progress in RWE, secure mobile patient data, rare disease, adherence and medicines and device safety agendas.

Read more